DE3232873A1 - Pharmazeutisches praeparat - Google Patents
Pharmazeutisches praeparatInfo
- Publication number
- DE3232873A1 DE3232873A1 DE19823232873 DE3232873A DE3232873A1 DE 3232873 A1 DE3232873 A1 DE 3232873A1 DE 19823232873 DE19823232873 DE 19823232873 DE 3232873 A DE3232873 A DE 3232873A DE 3232873 A1 DE3232873 A1 DE 3232873A1
- Authority
- DE
- Germany
- Prior art keywords
- dopa
- weight
- hydrocolloid
- mixture
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 50
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- 239000002775 capsule Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 26
- 239000000416 hydrocolloid Substances 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 17
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 11
- 230000003111 delayed effect Effects 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 230000005484 gravity Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- NNBNKIMRZZMHMX-UHFFFAOYSA-N Cl.NC(CO)C(=O)N(N)CC1=C(C(=C(C=C1)O)O)O Chemical compound Cl.NC(CO)C(=O)N(N)CC1=C(C(=C(C=C1)O)O)O NNBNKIMRZZMHMX-UHFFFAOYSA-N 0.000 claims description 8
- -1 2,3,4-trihydroxybenzyl Chemical group 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940096529 carboxypolymethylene Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 28
- 239000003826 tablet Substances 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DCXFYQVKCSSEJG-UHFFFAOYSA-N 4-(hydrazinylmethyl)benzene-1,2,3-triol;hydrochloride Chemical compound Cl.NNCC1=CC=C(O)C(O)=C1O DCXFYQVKCSSEJG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ULFCBIUXQQYDEI-UHFFFAOYSA-N benserazide hydrochloride Chemical compound Cl.OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O ULFCBIUXQQYDEI-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000011436 cob Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30149881A | 1981-09-14 | 1981-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3232873A1 true DE3232873A1 (de) | 1983-03-31 |
Family
ID=23163649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823232873 Ceased DE3232873A1 (de) | 1981-09-14 | 1982-09-03 | Pharmazeutisches praeparat |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS5857315A (bg) |
| AT (1) | AT385199B (bg) |
| BE (1) | BE894376A (bg) |
| BG (1) | BG60526B2 (bg) |
| CH (1) | CH652025A5 (bg) |
| DE (1) | DE3232873A1 (bg) |
| FR (1) | FR2512676B1 (bg) |
| GB (1) | GB2105590B (bg) |
| IT (1) | IT1158048B (bg) |
| MX (1) | MX9203173A (bg) |
| NL (1) | NL190746C (bg) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3527852A1 (de) * | 1984-08-03 | 1986-02-20 | Nippon Shinyaku Co., Ltd., Kyoto | Pharmazeutische zubereitung und verfahren zu ihrer herstellung |
| DE3642668A1 (de) * | 1986-12-13 | 1988-06-23 | Kamprad Joachim | Schmerzmittel fuer menschen |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| DE4101873A1 (de) * | 1991-01-23 | 1992-07-30 | Isis Chemie Gmbh | Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustaende |
| WO1994012153A1 (en) * | 1992-11-30 | 1994-06-09 | Nystroem Christer | A pharmaceutical formulation |
| DE102010023828A1 (de) * | 2010-06-15 | 2011-12-15 | IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH | Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält |
| US8642639B2 (en) | 2004-08-12 | 2014-02-04 | Kamprad KG | Formulation for L-tryptophane comprising carbidopa/benserazide |
| DE102022103658A1 (de) | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8507779D0 (en) * | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
| EP0198769A3 (en) * | 1985-04-12 | 1987-09-02 | Forest Laboratories, Inc. | Floating sustained release therapeutic compositions |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| ATE81971T1 (de) * | 1987-12-31 | 1992-11-15 | Asta Medica Ag | Synergistische kombination von decarboxylasehemmern und l-dopa-pellets. |
| EP0497977B1 (en) * | 1989-10-26 | 1995-03-15 | Nippon Shinyaku Company, Limited | Gastric preparation |
| US5227167A (en) * | 1991-06-11 | 1993-07-13 | Alza Corporation | Long-term delivery device including hydrophobic loading dose |
| US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| DE69423643T2 (de) * | 1993-10-29 | 2000-09-07 | Scherer Corp R P | Schäumende gelatinkapselfüllung |
| US5888540A (en) * | 1993-10-29 | 1999-03-30 | Sugden; Keith | Pharmaceutical products |
| EP0725626A1 (en) * | 1993-10-29 | 1996-08-14 | RECKITT & COLMAN PRODUCTS LIMITED | Gelatin capsule fill able to foam |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US20040180086A1 (en) * | 2002-10-11 | 2004-09-16 | Zebunnissa Ramtoola | Gastro-retentive levodopa delivery form |
| DE102014003744A1 (de) | 2014-03-10 | 2015-09-10 | Laboratorium für Lebensmittelwissenschaft (FPE) - Eidgenössische Technische Hochschule Zürich (ETH) | Produkt zur oralen Verabreichung bei Menschen oder Tieren mit mikrostrukturierten, gekapselten Inhaltsstoffen sowie Vorrichtung zum Herstellen eines derartigen Produkts und Verfahren zum Herstellen dieses Produkts |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3178476A (en) * | 1961-06-16 | 1965-04-13 | Hoffmann La Roche | Di-or tri-hydroxybenzyl hydrazides |
| US3557292A (en) * | 1968-08-16 | 1971-01-19 | Hoffmann La Roche | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine |
| US3632778A (en) * | 1970-06-10 | 1972-01-04 | Hoffmann La Roche | Tablets containing l-dopa |
| DE2611041A1 (de) * | 1975-03-17 | 1976-10-14 | Hoffmann La Roche | Retard-formulierung |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA713877B (en) * | 1970-07-24 | 1972-03-29 | Hoffmann La Roche | Pharmaceutical composition |
| DE2305209A1 (de) * | 1972-02-14 | 1973-08-23 | Hoffmann La Roche | Pharmazeutisches praeparat |
| GB1430684A (en) * | 1972-06-26 | 1976-03-31 | Lowey H | Prolonged release lozenges |
-
1982
- 1982-08-13 CH CH4867/82A patent/CH652025A5/de not_active IP Right Cessation
- 1982-08-26 NL NL8203343A patent/NL190746C/xx not_active IP Right Cessation
- 1982-09-03 DE DE19823232873 patent/DE3232873A1/de not_active Ceased
- 1982-09-07 IT IT23147/82A patent/IT1158048B/it active Protection Beyond IP Right Term
- 1982-09-10 FR FR8215334A patent/FR2512676B1/fr not_active Expired
- 1982-09-13 BE BE0/208995A patent/BE894376A/fr not_active IP Right Cessation
- 1982-09-13 AT AT0341582A patent/AT385199B/de not_active IP Right Cessation
- 1982-09-13 GB GB08226087A patent/GB2105590B/en not_active Expired
- 1982-09-13 JP JP57158240A patent/JPS5857315A/ja active Granted
-
1992
- 1992-06-23 MX MX9203173A patent/MX9203173A/es unknown
-
1994
- 1994-02-21 BG BG98501A patent/BG60526B2/bg unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3178476A (en) * | 1961-06-16 | 1965-04-13 | Hoffmann La Roche | Di-or tri-hydroxybenzyl hydrazides |
| US3557292A (en) * | 1968-08-16 | 1971-01-19 | Hoffmann La Roche | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine |
| US3632778A (en) * | 1970-06-10 | 1972-01-04 | Hoffmann La Roche | Tablets containing l-dopa |
| DE2611041A1 (de) * | 1975-03-17 | 1976-10-14 | Hoffmann La Roche | Retard-formulierung |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
Non-Patent Citations (2)
| Title |
|---|
| CH-Z: Fortschritte der Arzneimittelforschung, Vol.9, 1966, S.265-271 mit Literaturvereichnis S. 295, Basel u. Stuttgart * |
| DE-Buch: Rote Liste 1982, Nr.69008 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3527852A1 (de) * | 1984-08-03 | 1986-02-20 | Nippon Shinyaku Co., Ltd., Kyoto | Pharmazeutische zubereitung und verfahren zu ihrer herstellung |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| DE3642668A1 (de) * | 1986-12-13 | 1988-06-23 | Kamprad Joachim | Schmerzmittel fuer menschen |
| DE4101873A1 (de) * | 1991-01-23 | 1992-07-30 | Isis Chemie Gmbh | Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustaende |
| WO1994012153A1 (en) * | 1992-11-30 | 1994-06-09 | Nystroem Christer | A pharmaceutical formulation |
| US8642639B2 (en) | 2004-08-12 | 2014-02-04 | Kamprad KG | Formulation for L-tryptophane comprising carbidopa/benserazide |
| DE102010023828A1 (de) * | 2010-06-15 | 2011-12-15 | IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH | Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält |
| DE102022103658A1 (de) | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
| WO2023156275A1 (en) | 2022-02-16 | 2023-08-24 | Joachim Kamprad | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2105590A (en) | 1983-03-30 |
| NL8203343A (nl) | 1983-04-05 |
| MX9203173A (es) | 1992-07-01 |
| JPS5857315A (ja) | 1983-04-05 |
| BG60526B2 (bg) | 1995-07-28 |
| IT1158048B (it) | 1987-02-18 |
| ATA341582A (de) | 1987-08-15 |
| CH652025A5 (de) | 1985-10-31 |
| JPH0341447B2 (bg) | 1991-06-24 |
| FR2512676B1 (fr) | 1987-01-23 |
| FR2512676A1 (fr) | 1983-03-18 |
| AT385199B (de) | 1988-02-25 |
| GB2105590B (en) | 1985-05-30 |
| NL190746C (nl) | 1994-08-01 |
| IT8223147A0 (it) | 1982-09-07 |
| NL190746B (nl) | 1994-03-01 |
| BE894376A (fr) | 1983-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3232873A1 (de) | Pharmazeutisches praeparat | |
| US4424235A (en) | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor | |
| DE60133538T2 (de) | Formulierung und tabletten mit guaifenesin mit verzögerter freisetzung | |
| DE69629797T2 (de) | Matrix zur gesteuerten freisetzung von arzneistoffen | |
| AT398165B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung | |
| DE3779933T2 (de) | Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung. | |
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE60319252T2 (de) | Formulierung von acetaminophen und tramadol mit verzögerter freisetzung | |
| DE69820287T2 (de) | Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst | |
| DE3783394T2 (de) | Arzneizubereitung zur oralen anwendung. | |
| DE3875705T2 (de) | Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe. | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
| DE69110592T2 (de) | Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode. | |
| AT398166B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) | |
| DE69913197T2 (de) | Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe | |
| EP0804172B1 (en) | Controlled release potassium dosage form | |
| DE60026459T2 (de) | Simethicon enthaltendes Abführmittel | |
| EP0069259A2 (de) | Bromhexin-Retardform und Verfahren zu ihrer Herstellung | |
| EP0486863A1 (de) | Antazida-Zubereitung mit verlängerter Magenverweilzeit | |
| EP1509207B1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| DE69111574T2 (de) | Polycarbophil-Kalzium enthaltendes Arzneimittel. | |
| DE3882765T2 (de) | Tabletten mit verzögerter Freisetzung auf der Basis von hochmolekularer Hydroxypropylmethylcellulose und Verfahren zu ihrer Herstellung. | |
| DE3909520A1 (de) | Feste, schnell zerfallende darreichungsformen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8101 | Request for examination as to novelty | ||
| 8105 | Search report available | ||
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN |
|
| 8127 | New person/name/address of the applicant |
Owner name: F. HOFFMANN-LA ROCHE AG, BASEL, CH |
|
| 8128 | New person/name/address of the agent |
Representative=s name: LEDERER, F., DIPL.-CHEM. DR., 8000 MUENCHEN RIEDER |
|
| 8131 | Rejection |